NCT04997200Completed
Effect of Sleep Deprivation on Breathlessness and Exercise Capacity in COPD
Effect of Sleep Deprivation on Breathlessness and Exercise Capacity in COPD: a Randomized Crossover Trial
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This is a randomized controlled cross-over trial designed to measure the effect of one night's sleep deprivation on exercise endurance, ventilation and breathlessness in outpatients with COPD.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 21 Jul 2021
- Start date
- 13 Sept 2021
- Primary completion date
- 24 Oct 2024
- Lead sponsor
- Skane University Hospital
- Diseases
- COPD
- NCT number
- NCT04997200
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 13 Sept 2021 to the primary completion date, 24 Oct 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with supplementary oxygen at rest or during exercise
Other
- Resting peripheral oxygen saturation (SpO2) \< 92%
- Night shift worker
- Hospitalization or clinical instability during the last four weeks
- Sleep disturbance, defined as a Pittsburgh Sleep Quality Index \>5 at baseline
- Contraindication to exercise testing in accordance with clinical practice guidelines (ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277)
- Expected survival shorter than six months as judged by the Investigator.
Who the study is looking for
- Age 18 years or older
- COPD diagnosed by physician in accordance with Global Initiative For Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD 2021), with a spirometric ratio of the forced expired volume in one second (FEV1) / forced vital capacity (FVC) \< 0.7 and a FEV1 \< 80% of predicted post bronchodilator at baseline.
- Self-reported average sleep time of six hours or longer during a normal night.
- No regular treatment with sleep medication or anxiolytics.
- Able to cycle
- Able to talk and write Swedish well enough to participate in the study procedures, as judged by the Investigator.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Blekinge Tekniska Högskola (BTH) Coordinator of this site? Confirm its status | Karlskrona | Sweden | Unknown status |
| Department of Clinical Physiology, Blekinge Hospital Coordinator of this site? Confirm its status | Karlskrona | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.